COVID-19 VACCINE

OVERVIEW There are currently no SARS-CoV-2-specific treatments or vaccines available due to the novelty of the virus. Hence, rapid Development of effective vaccines against SARS-CoV-2 are urgently needed. Hence, our Developer initiated R&D of COVID-19 vaccine on Jan. 28, 2020, and Phase 1 and 2 Trials were approved by NMPA on April 13, 2020. As of today, Phase 3 trials have been approved in Brazil, Indonesia, Turkey and Bangladesh. More than 30,000 subjects have been enrolled in these Phase 3 trials. Neutralizing antibodies successfully produced by the subjects’ body after 2 doses, providing partial or complete protection In macaques against Covid-19 challenge, with no adverse side effects observed in the subjects. INTERNATIONAL COORDINATION OF DEVELOPER                 DCVMN- Developing Countries Vaccine Manufacturers Network                 IFPMA- International Federation of Pharmaceutical Manufacturers & Associations                 WHO- World Health Organization                 PAHO- Pan America Health Organization                        UNICEF- FOR EVERY CHILD QUALITY ACCREDITATION OF DEVELOPER                 Total GMPs: 11 Certificates                 Toral MAs: 33 product Certificates TECHNOLOGY- based on inactivated whole vision technology. CAPACITY- over 300 million doses per year